La Jolla, CA5 Active Studies

Ovarian Cancer Clinical Trials in La Jolla, CA

Find 5 actively recruiting ovarian cancer clinical trials in La Jolla, CA. Connect with local research sites and explore new treatment options.

5
Active Trials
5
Sponsors
1,636
Enrolling

Recruiting Ovarian Cancer Studies in La Jolla

RecruitingLa Jolla, CANCT06619236

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to che...

530 participants
Genmab
View Study Details
RecruitingLa Jolla, CANCT05445778

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensiti...

520 participants
AbbVie
View Study Details
RecruitingLa Jolla, CANCT05659381

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Reg...

230 participants
GOG Foundation
View Study Details
RecruitingLa Jolla, CANCT05281471

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active...

186 participants
Genelux Corporation
View Study Details
RecruitingLa Jolla, CANCT05128825

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Canc...

170 participants
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
View Study Details

About Ovarian Cancer Clinical Trials in La Jolla

Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.

There are currently 5 ovarian cancer clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 1,636 participants. Research is being sponsored by Genmab, AbbVie, GOG Foundation and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ovarian Cancer Clinical Trials in La Jolla — FAQ

Are there ovarian cancer clinical trials in La Jolla?

Yes, there are 5 ovarian cancer clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What ovarian cancer treatments are being tested?

The 5 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.

Data updated March 2, 2026 from ClinicalTrials.gov